Arterial Stiffness Use for Early Monitoring of Cardiovascular Adverse Events due to Anthracycline Chemotherapy in Breast Cancer Patients. A Pilot Study
Open Access
- 1 January 2018
- journal article
- research article
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 111 (5) , 721-727
Abstract
Background: Chemotherapy with doxorubicin and cyclophosphamide, although efficient for treating breast cancer, is associated with cardiovascular complications. Recent studies seek to identify methods that can early detect cardiological and vascular changes as a strategy to decrease the incidence of cardiovascular comorbidities. Objective: To evaluate the role of arterial stiffness measurement in the monitoring of doxorubicin and cyclophosphamide-induced cardiotoxicity in breast cancer patients. Methods: Prospective longitudinal study in 24 breast cancer patients undergoing treatment with doxorubicin and cyclophosphamide. Patients underwent an indirect evaluation of arterial stiffness through non-invasive measurement of hemodynamic parameters such as pulse wave velocity with the Mobil-O-Graph (R) 24H PWA device at three different times of the chemotherapy treatment (pre-chemotherapy, after the first and the fourth cycle). The left ventricular ejection fraction was also evaluated by Doppler echocardiography (pre-chemotherapy and after the fourth chemotherapy cycle). Data were considered significant when p <= 0.05. Results: Patients had a mean age of 52.33 +/- 8.85 years and body mass index of 31 +/- 5.87 kg/m(2). There was no significant difference between the hemodynamic parameters evaluated by the oscillometric method or in the left ventricular ejection fraction in the different evaluated periods. Conclusion: Evaluations of arterial stiffness by oscillometry and measurement of left ventricular ejection fraction by Doppler echocardiography showed equivalence in the values found, suggesting that the evaluation method of arterial stiffness studied could be used as a marker for cardiovascular adverse events associated with doxorrubicin-based chemotherapy drugs.Keywords
This publication has 35 references indexed in Scilit:
- Cardiovascular disease among breast cancer survivors: the call for a clinical vascular health toolboxBreast Cancer Research and Treatment, 2013
- Low to Moderate Dose Anthracycline-Based Chemotherapy Is Associated With Early Noninvasive Imaging Evidence of Subclinical Cardiovascular DiseaseJACC: Cardiovascular Imaging, 2013
- Prospective surveillance and management of cardiac toxicity and health in breast cancer survivorsCancer, 2012
- Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) TrialJournal of Clinical Oncology, 2010
- Aortic Stiffness Increases Upon Receipt of Anthracycline ChemotherapyJournal of Clinical Oncology, 2010
- Cardiotoxic drugs: clinical monitoring and decision makingHeart, 2008
- Adjuvant Chemotherapy Following Neoadjuvant Therapy of Rectal Cancer: The Type of Neoadjuvant Therapy (chemoradiotherapy or radiotherapy) May Be Important for Selection of PatientsJournal of Clinical Oncology, 2008
- Monitoring Left Ventricular Function in Adults Receiving Anthracycline-Containing ChemotherapyEuropean Journal of Heart Failure, 2007
- Projections of Global Mortality and Burden of Disease from 2002 to 2030PLOS Medicine, 2006
- Risk Factors for Doxorubicin-lnduced Congestive Heart FailureAnnals of Internal Medicine, 1979